查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466077

肺部疾病藥物市場：按藥物類別、按適應症、按藥物類型、按分銷管道、按最終用戶分類 - 全球預測 2024-2030

Pulmonary Drugs Market by Drug Class (Anti-Cholinergic Agents, Anti-Leukotrienes, Antihistamines), Indication (Allergic Rhinitis, Asthma, Chronic Obstructive Pulmonary Disease), Drug Type, Distribution Channel, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年肺病治療市場規模為793.5億美元，預計2024年將達861.4億美元，2030年將達1362.7億美元，複合年成長率為8.03%。

肺部疾病治療市場包括專為預防、診斷和治療呼吸系統疾病而設計的各種治療解決方案。肺部疾病藥物主要用於治療多種呼吸系統疾病，包括肺炎、結核病、氣喘、慢性阻塞性肺病（COPD）、囊腫纖維化、過敏性鼻炎和其他肺部疾病。肺部疾病盛行率的上升以及政府促進疾病治療的努力增加了對治療肺部疾病的藥物的需求。改善的報銷政策和政府對肺病藥物的有利核准也有助於市場成長。然而，產品召回事件可能會限制肺病藥物的採用。與藥物傳遞不足和抗藥性發展相關的限制預計也將對採用治療肺部疾病的藥物構成挑戰。此外，用於治療肺部疾病的新生技藥品和標靶藥物的開發以及吸入藥物輸送療法的進步預計將為市場提供潛在的成長機會。

主要市場統計
基準年[2023] 793.5億美元
預測年份 [2024] 861.4億美元
預測年份 [2030] 1362.7億美元
複合年成長率（%） 8.03%

按藥物類別：組合藥物和單株抗體開發的進展使肺部疾病的個人化治療成為可能

抗膽鹼能藥物是一類阻斷乙醯膽鹼作用的藥物，乙醯膽鹼是一種負責在氣道中傳遞衝動的神經傳導物質。這些藥物透過減少支氣管收縮和氣道分泌物來發揮作用，可用於治療慢性阻塞性肺病（COPD）和氣喘。抗白三烯藥物是一種透過阻斷白三烯的作用來對抗呼吸系統發炎的藥物，白三烯是參與免疫反應的化學物質，導致氣道收縮和黏液產生。它主要用於治療氣喘，特別是對吸入性皮質類固醇和BETA2促效劑等常規治療沒有反應的患者。抗組織胺藥物透過抑制組織胺（過敏反應過程中釋放的化學信使）發揮作用，並減少過敏症狀，如打噴嚏、搔癢和鼻塞。抗組織胺有助於治療氣喘和與過敏相關的慢性鼻炎，但主要針對肺部疾病。 Beta2促效劑是一種肺部疾病藥物，可刺激支氣管平滑肌細胞上的 BETA2 腎上腺素受體，引起支氣管鬆弛和擴張，這對於控制氣喘和慢性阻塞性肺病的症狀至關重要。組合藥物將兩種或多種不同類別的藥物結合起來，以提高療效，同時最大限度地減少副作用。當單一療法無法充分控制症狀時，通常會開藥。單株抗體是生物藥品，旨在針對參與發炎和免疫介導的氣道疾病（例如嚴重氣喘）的特定細胞路徑。口服和吸入的皮質類固醇是強效發炎藥，用於治療多種肺部疾病，如氣喘和慢性阻塞性肺病。

需要有效的藥物和用於治療和管理 COPD 和囊腫纖維化的藥物

過敏性鼻炎是一種因接觸花粉、塵蟎和動物皮屑等過敏原而影響鼻道的發炎疾病。最常用於治療這種情況的藥物包括抗組織胺、白三烯受體拮抗劑和鼻用皮質類固醇。支氣管氣喘是一種以氣道阻塞和支氣管痙攣為特徵的慢性發炎呼吸道疾病。根據嚴重程度和患者個別需求，氣喘治療可能包括使用短效 BETA 受體促效劑(SABA)、長效 BETA 受體促效劑(LABA)、吸入性皮質類固醇 (ICS) 或生物製藥。慢性阻塞性肺病（COPD）是一種與慢性支氣管炎和肺氣腫相關的肺部疾病，導致氣流阻塞。囊腫纖維化是一種遺傳性疾病，會導致肺部黏液積聚，導致慢性感染疾病和呼吸衰竭。主要治療方法是用調節藥物靶向有缺陷的囊腫纖維化跨膜電導調節蛋白（CFTR），並用支氣管擴張劑、抗生素和粘液溶解劑控制症狀。肺動脈高血壓（PAH）是一種罕見嚴重的疾病，患者為肺部供血的動脈血壓升高。用於治療 PAH 的主要藥物類別包括內皮素受體拮抗劑 (ERA)、前列腺環素類似物或促效劑、可溶性鳥苷酸環化酶促效劑(sGCS) 和5 型磷酸二酯酶抑制劑( PDE-5i)。

藥物類型 在肺部疾病管理中越來越偏好具有成本效益的學名藥

處方藥是需要醫療保健專業人員處方箋才能分發給患者的藥物。這些藥物在獲得食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 等政府機構核准之前，都會經過嚴格的測試和監管流程，以確保安全性和有效性。肺部處方藥提供具有先進作用機制的標靶治療，旨在解決呼吸系統疾病的根本原因。學名藥在劑型、規格、給藥途徑、品質、性能特徵和預期用途方面與品牌藥在生物學上等效。這些藥物在品牌藥的專利到期後被引入市場，並且通常以低於品牌藥的價格出售。成本效益是需要長期治療的醫療保健提供者和無力負擔費用的患者偏好學名藥的一個主要因素。

分銷管道：改善線上分銷策略，提高產品在患者和醫療保健專業人員中的滲透率

醫院藥局是肺部藥物的重要分銷管道，主要是因為它們策略性地位置醫療機構內。這使得醫護人員能夠快速為患有慢性和急性呼吸道疾病的患者提供救命藥物。網路藥局已成為購買肺部疾病藥物的便捷且經濟高效的平台。網路藥局提供到府外送、隱私、折扣等優勢，無需去藥局即可輕鬆取得藥物。零售藥局因其分佈廣泛且患者易於取得而成為肺部疾病藥物的重要分銷管道。

最終使用者：為醫院的急性病例和嚴重呼吸道疾病提供多種速效藥物。

在居家醫療領域，患有氣喘、肺結核、慢性阻塞性肺病（COPD）等慢性呼吸系統疾病的患者需要定期用藥和管理。醫院是治療呼吸系統疾病急性發作和重症病例的重要中心。專科診所為患有特定呼吸系統疾病的患者提供服務，包括囊腫纖維化、間質性肺病和肺動脈高血壓（PAH）。

區域洞察

由於該地區存在主要市場參與者，美洲地區擁有高度發展的肺科藥物製造基礎設施。在美國、加拿大、巴西等主要國家，慢性阻塞性肺病、結核病、氣喘等呼吸道疾病在兒童和成人中流行，增加了對治療肺部疾病藥物的需求。德國、法國、義大利和西班牙等歐洲、中東和非洲國家由於人口老化，呼吸道疾病的盛行率也很高，促進了該地區的市場成長。沙烏地阿拉伯和阿拉伯聯合大公國等中東國家正大力投資改善其衛生基礎設施，以解決這個公共衛生問題。由於中國、印度和日本等主要國家政府投資的增加，亞洲地區的市場正在成長。該地區的市場相關人員專注於生產負擔得起的肺部疾病學名藥，並投資國內新藥開拓。

FPNV定位矩陣

FPNV定位矩陣對於評估肺病藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對肺病藥物市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.肺病治療藥物市場規模及預測是多少？

2.肺病藥物市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3.肺病治療藥物市場的技術趨勢與法規結構是什麼？

4.肺病治療藥物市場主要廠商的市場佔有率是多少？

5.進入肺病藥物市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 努力解決肺部疾病的流行問題並促進疾病治療和藥物獲取
      • 改善肺部疾病藥物的報銷並獲得有利的政府核准
    • 抑制因素
      • 用於治療肺部疾病的藥物召回增加
    • 機會
      • 開發治療肺部疾病的新型生物製藥和標靶藥物
      • 吸入藥物傳遞療法和技術的進展
    • 任務
      • 與不適當的藥物傳遞和抗藥性發展相關的限制
  • 市場區隔分析
    • 藥物類別：合併藥物和單株抗體製劑的進展，為肺部疾病提供個人化治療
    • 適應症：需要有效的藥物來治療和管理慢性阻塞性肺病和囊腫纖維化
    • 藥物類型：治療肺部疾病的趨勢有利於具有成本效益的學名藥
    • 分銷管道：改善線上分銷策略，提高產品在患者和醫療保健提供者中的滲透率
    • 最終使用者：提供各種速效藥物來治療醫院的急性病例和嚴重呼吸道疾病。
  • 市場趨勢分析
    • 由於呼吸系統疾病盛行率上升以及主要市場參與者開發用於疾病管理的創新肺部疾病治療方法，預計美洲將顯著成長。
    • 亞太地區創新肺病治療藥物共同生產的既定空間得到了政府對藥物商業化的財政支持的大力支持。
    • 改善的醫療基礎設施和政府支援將重點放在研發以滿足歐洲、中東和非洲地區肺病藥物的需求
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析

第6章依藥物類別分類的肺部疾病治療藥物市場

  • 抗膽鹼能藥
  • 抗白三烯
  • 抗組織胺藥
  • BETA2促效劑
  • 伴隨藥物
  • 單株抗體
  • 口服和吸入性皮質類固醇

第7章依適應症分類的肺部疾病治療藥物市場

  • 過敏性鼻炎
  • 氣喘
  • 慢性阻塞性肺病
  • 囊腫纖維化
  • 肺動脈高血壓

第8章依藥品類型分類的肺部疾病治療藥品市場

  • 學名藥
  • 處方藥

第9章肺部疾病治療藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章肺部疾病治療藥物市場：依最終使用者分類

  • 居家護理
  • 醫院
  • 專科診所

第11章 北美和南美肺部疾病治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太肺部疾病治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲肺部疾病治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • Bridge Biotherapeutics 宣布獨立資料監測委員會對特發性肺纖維化 BBT-877 2a 期研究給予積極建議
    • 百時美施貴寶宣布美國FDA 授予臨床實驗LPA1 拮抗劑用於治療進行性肺纖維化的突破性療法
    • 隨著氣喘資金籌措的加速推進，Aeolus Bio 斥資 2.45 億美元啟動
    • Avalin 籌集 1.75 億美元資金用於開發 IPF 吸入器
    • Lupin 與 Mark Cuban 和慢性阻塞性肺病基金會 (COPD Foundation) 合作，擴大美國慢性阻塞性肺病 (COPD) 治療的可及性
    • Apollo Therapeutics 籌集 2.265 億美元用於研究型藥物開發
    • Viatris 與 Quindeva 合作，宣布推出 Breina（Budesonide和Formoterol福莫特羅二水合物）吸入氣霧劑，這是 FDA核准的Symbicort非專利藥，用於氣喘和慢性阻塞性肺病患者
    • 美國FDA核准輝瑞疫苗「ABRYSVO」用於預防老年人呼吸道融合病毒（RSV）（RSV）
    • TFF 和 NIEHS 合作開發治療呼吸道疾病的粉末製劑
    • 美國FDA核准葛蘭素史克老年人呼吸道融合病毒（RSV）（RSV）疫苗“Alexi”
    • Astra Zeneca推出新型氣喘治療藥物“Air Supra”
    • C4XD 與Astra Zeneca簽署 4.02 億美元協議，開發呼吸系統疾病治療藥物

第15章競爭組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-4316E4E893EF

[198 Pages Report] The Pulmonary Drugs Market size was estimated at USD 79.35 billion in 2023 and expected to reach USD 86.14 billion in 2024, at a CAGR 8.03% to reach USD 136.27 billion by 2030.

The pulmonary drugs market encompasses a wide range of therapeutic solutions specifically designed for the prevention, diagnosis, and treatment of respiratory diseases. Pulmonary drugs are primarily used in treating various respiratory conditions such as pneumonia, tuberculosis, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, allergic rhinitis, and other pulmonary ailments. The rising prevalence of pulmonary diseases and government initiatives to promote disease treatment have increased the need for pulmonary drugs. The improvements in reimbursement policies and favorable government approvals for pulmonary drugs also contribute to market growth. However, incidents of product recalls may limit the adoption of pulmonary drugs. The limitations associated with improper drug delivery and the development of drug resistance are also expected to create challenges in the adoption of pulmonary drugs. Moreover, The development of new biologics & targeted drugs for pulmonary disease treatment and advancements in inhaled drug delivery therapies are expected to create potential growth opportunities in the market.

KEY MARKET STATISTICS
Base Year [2023] USD 79.35 billion
Estimated Year [2024] USD 86.14 billion
Forecast Year [2030] USD 136.27 billion
CAGR (%) 8.03%

Drug Class: Advancements in the formulations of combination drugs and monoclonal antibodies to offer personalized treatment of pulmonary diseases

Anticholinergic agents are a class of drugs that block the action of acetylcholine, a neurotransmitter responsible for transmitting impulses in the airways. These medications help reduce bronchoconstriction and airway secretions, making them useful for treating chronic obstructive pulmonary disease (COPD) and asthma. Anti-leukotrienes are medications that combat inflammation in the respiratory system by blocking the effects of leukotrienes, which are chemicals involved in immune responses leading to airway constriction and mucus production. They are used primarily to treat asthma, especially in patients who do not respond well to traditional treatments such as inhaled corticosteroids or beta-2 agonists. Antihistamines work by inhibiting histamine, a chemical mediator released during allergic reactions, thereby reducing allergy symptoms such as sneezing, itching, and nasal congestion. Antihistamines can be beneficial in treating asthma and chronic rhinitis associated with allergies; however, it is primarily intended for pulmonary conditions. Beta-2 agonists are pulmonary drugs that stimulate beta-2 adrenergic receptors on bronchial smooth muscle cells, causing relaxation and bronchodilation, which is essential for managing asthma and COPD symptoms. Combination drugs contain two or more different classes of medications to enhance efficacy while minimizing side effects. They are often prescribed when single-agent therapies do not provide adequate symptom control. Monoclonal antibodies are biological drugs engineered to target specific cellular pathways involved in inflammatory and immune-mediated airway diseases, such as severe asthma. Corticosteroids, both oral and inhaled, are potent anti-inflammatory agents used to treat various pulmonary disorders such as asthma and COPD.

Indication: Need for effective drugs and medications to treat and manage COPD and cystic fibrosis

Allergic rhinitis is an inflammatory condition that impacts the nasal passages due to exposure to allergens, including pollen, dust mites, or animal dander. The most commonly used medications for managing this condition include antihistamines, leukotriene receptor antagonists, and intranasal corticosteroids. Asthma is a chronic inflammatory respiratory disease portraying airway obstruction and bronchospasm. Depending on the severity and individual patient needs, asthma management can involve short-acting beta-agonists (SABAs), long-acting beta-agonists (LABAs), inhaled corticosteroids (ICS), or biologics. Chronic obstructive pulmonary disease (COPD) is a lung disease involving chronic bronchitis and emphysema that results in airflow obstruction. Cystic fibrosis, a genetic disorder, causes the accumulation of thick mucus in the lungs, causing chronic infections and respiratory failure. The primary treatment approach involves targeting the defective cystic fibrosis transmembrane conductance regulator (CFTR) protein with modulators and managing symptoms using bronchodilators, antibiotics, and mucolytics. Pulmonary arterial hypertension (PAH) is a rare, severe disorder leading to high blood pressure in the arteries supplying blood to the lungs. The main classes of drugs utilized to treat PAH include endothelin receptor antagonists (ERAs), prostacyclin analogs or agonists, soluble guanylate cyclase stimulators (sGCS), and phosphodiesterase type 5 inhibitors (PDE-5i).

Drug Type: Emerging preference for cost-effective generic medications for pulmonary disease management

Prescription drugs are medications that require a prescription from a licensed healthcare professional before they can be dispensed to patients. These medications undergo rigorous testing and regulatory processes to ensure safety and efficacy before being approved by governing agencies such as the Food & Drug Administration (FDA) or the European Medicines Agency (EMA). Prescription pulmonary drugs offer targeted therapies with advanced mechanisms of action designed to address the underlying causes of respiratory diseases. Generic drugs are bioequivalent to branded drugs in dosage form, strength, route of administration, quality, performance characteristics, and intended use. These drugs enter the market after the patent expiration of their branded counterparts and are typically priced lower than the original products. The cost-effectiveness is a primary factor driving the preference for generic drugs among healthcare providers and patients who require long-term treatments or have limited financial resources.

Distribution Channel: Improvements in online distribution strategies for better product penetration among patients and healthcare providers

Hospital pharmacies are an essential distribution channel for pulmonary drugs, primarily due to their strategic location within healthcare facilities. This enables healthcare professionals to have immediate access to life-saving medications for patients with chronic and acute respiratory disorders. Online pharmacies have emerged as a convenient and cost-effective platform for purchasing pulmonary drugs. They offer advantages such as doorstep delivery, privacy, discounts, and ease of access to medications without needing a physical visit to a pharmacy store. Retail pharmacies constitute a significant distribution channel for pulmonary drugs, owing to their widespread presence and ease of access for patients.

End-User: Availability of a versatile range of drugs with rapid onset action to address acute cases and severe respiratory disorders in hospitals

In the homecare segment, patients with chronic respiratory diseases, including asthma, tuberculosis, and chronic obstructive pulmonary disease (COPD) require regular medication and management. Hospitals serve as critical centers for the treatment of acute exacerbations and severe cases of respiratory disorders. Specialty clinics cater to patients with specific respiratory conditions, including cystic fibrosis, interstitial lung diseases, and pulmonary arterial hypertension (PAH).

Regional Insights

The Americas region has a highly developed infrastructure for manufacturing of pulmonary drugs due to the presence of major market players in the area. In major countries such as the United States, Canada, and Brazil, respiratory diseases such as Chronic Obstructive Pulmonary Disease, Tuberculosis, and Asthma are prevalent among both children and adults, increasing the need for pulmonary drugs. EMEA countries, including Germany, France, Italy, Spain, and others, also have a high prevalence of respiratory disorders owing to the growing aging population, contributing to the market growth in the region. Middle-East countries such as Saudi Arabia and the UAE have invested heavily in health infrastructure improvements to address this public health concern. The Asian region is witnessing market growth due to increasing government investments in major countries such as China, India, and Japan. The market players in the region concentrate on producing affordable generics for pulmonary conditions and investing in the development of new drugs domestically.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Pulmonary Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pulmonary Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Pulmonary Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Chiesi Farmaceutici S.p.A, Cipla Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Grifols, S.A., Icosavax, Inc., Johnson & Johnson Services, Inc., Lung Therapeutics Inc., Lupin Pharmaceuticals, Inc., Mallinckrodt PLC, Merck & Co., Inc., Novartis AG, Pfizer Inc., Pieris Pharmaceuticals, Inc., Sanofi S.A, Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, Verona Pharma PLC, Vertex Pharmaceuticals Incorporated, Viatris Inc., and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Pulmonary Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Anti-Cholinergic Agents
    • Anti-Leukotrienes
    • Antihistamines
    • Beta-2 Agonists
    • Combination Drugs
    • Monoclonal Antibodies
    • Oral & Inhaled Corticosteroids
  • Indication
    • Allergic Rhinitis
    • Asthma
    • Chronic Obstructive Pulmonary Disease
    • Cystic Fibrosis
    • Pulmonary Arterial Hypertension
  • Drug Type
    • Generic Drugs
    • Prescription Drugs
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End-User
    • Homecare
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Pulmonary Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pulmonary Drugs Market?

3. What are the technology trends and regulatory frameworks in the Pulmonary Drugs Market?

4. What is the market share of the leading vendors in the Pulmonary Drugs Market?

5. Which modes and strategic moves are suitable for entering the Pulmonary Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of pulmonary diseases and initiatives to promote disease treatment and drug accessibility
      • 5.1.1.2. Improvements in reimbursements and favorable government approvals for pulmonary drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Increasing recall of drugs used for pulmonary conditions
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of new biologics and targeted drugs for pulmonary disease treatment
      • 5.1.3.2. Advancements in inhaled drug delivery therapies and technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations associated with improper drug delivery and development of drug resistance
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Advancements in the formulations of combination drugs and monoclonal antibodies to offer personalized treatment of pulmonary diseases
    • 5.2.2. Indication: Need for effective drugs and medications to treat and manage COPD and cystic fibrosis
    • 5.2.3. Drug Type: Emerging preference for cost-effective generic medications for pulmonary disease management
    • 5.2.4. Distribution Channel: Improvements in online distribution strategies for better product penetration among patients and healthcare providers
    • 5.2.5. End-User: Availability of a versatile range of drugs with rapid onset action to address acute cases and severe respiratory disorders in hospitals
  • 5.3. Market Trend Analysis
    • 5.3.1. Significant growth in the Americas due to rising respiratory disease prevalence and the presence of major market players developing innovative pulmonary drugs for disease management.
    • 5.3.2. Well-established space for collaborative production of innovative pulmonary drugs in the Asia-Pacific substantially backed by the government's financial support for drug commercialization
    • 5.3.3. Improving healthcare infrastructure and government support emphasize research and development to meet the pulmonary drug requirement in EMEA
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Pulmonary Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anti-Cholinergic Agents
  • 6.3. Anti-Leukotrienes
  • 6.4. Antihistamines
  • 6.5. Beta-2 Agonists
  • 6.6. Combination Drugs
  • 6.7. Monoclonal Antibodies
  • 6.8. Oral & Inhaled Corticosteroids

7. Pulmonary Drugs Market, by Indication

  • 7.1. Introduction
  • 7.2. Allergic Rhinitis
  • 7.3. Asthma
  • 7.4. Chronic Obstructive Pulmonary Disease
  • 7.5. Cystic Fibrosis
  • 7.6. Pulmonary Arterial Hypertension

8. Pulmonary Drugs Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Generic Drugs
  • 8.3. Prescription Drugs

9. Pulmonary Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Pulmonary Drugs Market, by End-User

  • 10.1. Introduction
  • 10.2. Homecare
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Americas Pulmonary Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Pulmonary Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Pulmonary Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis
    • 14.3.2. Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
    • 14.3.3. Aiolos Bio Launches With USD 245 millions As Asthma-Focused Funding Accelerates
    • 14.3.4. Avalyn Raises USD 175 Million in Funding to Develop Inhaled IPF Drugs
    • 14.3.5. Lupin Partners With Mark Cuban and COPD Foundation to Expand Access to COPD Medication in the US
    • 14.3.6. Apollo Therapeutics Raises USD 226.5 million to Develop Medicines Based on Uni Research
    • 14.3.7. Viatris Announces Launch of Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the FDA-Approved Generic Version of Symbicort for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva
    • 14.3.8. U.S. FDA Approves ABRYSVO, Pfizer's Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
    • 14.3.9. TFF and NIEHS Partner to Develop Powder Formulations for Respiratory Diseases
    • 14.3.10. US FDA Approves GSK's Arexvy, a Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
    • 14.3.11. AstraZeneca Launches New Asthma Medication Called Airsupra
    • 14.3.12. C4XD and AstraZeneca Enter USD 402 million Deal to Develop Respiratory Disease Therapy

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PULMONARY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. PULMONARY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PULMONARY DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. PULMONARY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. PULMONARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PULMONARY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-CHOLINERGIC AGENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-CHOLINERGIC AGENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-LEUKOTRIENES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-LEUKOTRIENES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BETA-2 AGONISTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BETA-2 AGONISTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL PULMONARY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL PULMONARY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL & INHALED CORTICOSTEROIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL & INHALED CORTICOSTEROIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY ARTERIAL HYPERTENSION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY ARTERIAL HYPERTENSION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 136. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 140. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 142. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 145. CHINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 146. CHINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 147. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. CHINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. CHINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. CHINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 152. CHINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 155. INDIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 156. INDIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 157. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. INDIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 160. INDIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 161. INDIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 162. INDIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 165. INDONESIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 166. INDONESIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 167. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 170. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 171. INDONESIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 172. INDONESIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 175. JAPAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 176. JAPAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 177. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. JAPAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 180. JAPAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 181. JAPAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 182. JAPAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 185. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 186. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 187. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 192. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 196. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 200. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 202. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 205. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 206. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 207. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 210. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 211. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 212. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 216. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 220. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 222. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 225. TAIWAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 226. TAIWAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 227. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 230. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 231. TAIWAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 232. TAIWAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 235. THAILAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 236. THAILAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 237. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. THAILAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 240. THAILAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 241. THAILAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 242. THAILAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 245. VIETNAM PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 246. VIETNAM PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 247. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 250. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 251. VIETNAM PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 252. VIETNAM PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 267. DENMARK PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 268. DENMARK PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 269. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. DENMARK PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 272. DENMARK PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 273. DENMARK PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 274. DENMARK PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 277. EGYPT PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 278. EGYPT PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 279. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. EGYPT PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 282. EGYPT PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 283. EGYPT PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 284. EGYPT PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 287. FINLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 288. FINLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 289. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. FINLAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 292. FINLAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 293. FINLAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 294. FINLAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 295. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 296. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 297. FRANCE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 298. FRANCE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 299. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. FRANCE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 302. FRANCE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 303. FRANCE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 304. FRANCE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 305. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 306. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 307. GERMANY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 308. GERMANY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 309. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. GERMANY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 312. GERMANY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 313. GERMANY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 314. GERMANY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 315. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 316. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 317. ISRAEL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 318. ISRAEL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 319. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 322. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 323. ISRAEL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 324. ISRAEL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 325. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 326. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 327. ITALY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 328. ITALY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 329. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 330. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 331. ITALY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 332. ITALY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 333. ITALY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 334. ITALY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 335. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 336. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 337. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 338. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 339. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 340. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 341. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 342. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 343. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 344. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 345. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 346. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 347. NIGERIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 348. NIGERIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 349. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 350. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 351. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 352. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 353. NIGERIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 354. NIGERIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 355. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 356. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 357. NORWAY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 358. NORWAY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 359. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 360. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 361. NORWAY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)

TABLE